13 results about "Vincristine" patented technology

The invention discloses a combined pharmaceutical composition for preventing, relieving or treating acute myelogenous leukemia and application, and relates to the technical field of biomedicine. The invention provides a combined pharmaceutical composition for preventing, relieving or treating acute myelogenous leukemia. The combined pharmaceutical composition comprises vincristine and cytarabine or pharmaceutically acceptable salts and solvates of the vincristine and the cytarabine. According to the vincristine and cytarabine combined pharmaceutical composition, the apoptosis level of acute myelogenous leukemia cells can be remarkably improved, and compared with single-drug treatment, the vincristine and cytarabine combined pharmaceutical composition has higher anti-tumor efficacy; vincristine interferes or blocks a cell senescence state induced by cytarabine through a microtubule destruction effect, so that the problem of drug insensitivity caused by cell senescence is solved, and drug resistance caused by cell senescence is effectively reversed.

The invention relates to the technical field of biological medicine, in particular to application of a creatine related gene detection reagent in preparation of breast cancer prognosis products. The creatine related gene is an IGFBP1 gene and / or a TBC1D4 gene. According to the method, the expression levels of IGFBP1 and TBC1D4 genes in breast cancer patient samples are detected, a risk score is calculated by using a random survival forest (RSF) model, and the one-year, two-year and three-year survival rates of breast cancer patients are accurately predicted according to the risk score result. Meanwhile, the invention proves that IGFBP1 and TBC1D4 genes can be used as potential targets for breast cancer treatment, the IGFBP1 and fulvestrant as well as the TBC1D4 and vinblastine have stable binding capacity, and a new basis is provided for selection of individualized treatment medicines for breast cancer.

Disclosed are methods, compositions, and kits for treating pediatric cancers using hydroxyureamethyl acylfulvene (LP-184) or pharmaceutically acceptable salts / solvates thereof. The methods include monotherapy and combination regimens for pediatric sarcoma, medulloblastoma, glioma (including DIPG), hepatoblastoma, Wilms tumor, and related malignancies. Combination therapies include LP-184 with vincristine, topoisomerase I poisons (topotecan or irinotecan), PARP inhibitors (e.g., rucaparib), or spironolactone, yielding additive or greater-than-additive reductions in tumor growth or cell viability.

The present invention belongs to the field of medical technology, and specifically relates to a polypeptide for relieving vincristine-induced neuropathic pain and its application. The polypeptide of the present invention for relieving vincristine-induced neuropathic pain is a polypeptide with an amino acid sequence as shown in SEQ ID NO: 1, and is named polypeptide XXW-001. The polypeptide provided by the present invention for relieving vincristine-induced neuropathic pain in rats has low toxic side effects on individuals; the polypeptide XXW-001 of the present invention only needs to be dissolved in physiological saline, and the solvent has extremely low impact on the living body; the analgesic effect is obvious, and it can be used to treat vincristine-induced allodynia; it does not cause significant side effects such as depression, anxiety or addiction, and is suitable for long-term administration.

The present application relates to a kind of isoquinoline alkaloid derivatives for reversing tumor multidrug resistance by inhibiting autophagy and preparation method and application.The derivative can efficiently reverse the multidrug resistance of various solid tumor cells such as gastric cancer, lung cancer and esophageal cancer, the derivative can inhibit the autophagy flow of tumor cells, it is combined with vincristine, mitoxantrone, colchicine, docetaxel and various chemotherapeutic drugs, can efficiently reverse tumor multidrug resistance in vivo and in vitro, this kind of derivative has excellent oral bioavailability and lower toxic side effects, provides a kind of alternative strategy for autophagy inhibitor as antitumor chemosensitizer, can be used as lead compound for the research and development of new drug-resistant tumor reversing agent.

The application provides a use of vincristine and lithium carbonate as co-active ingredients in the preparation of a medicament for treating tumors. The vincristine and lithium carbonate as co-active ingredients of the application have a killing effect on various leukemia cells, including human acute lymphoblastic leukemia cell lines, chronic myeloid leukemia cells, acute monocytic leukemia cell lines; in particular, for human acute lymphoblastic leukemia cell lines, compared with single free drugs (lithium carbonate or vincristine), lithium carbonate and vincristine free drug combination, the leukemia cell proliferation can be more effectively inhibited; in addition, the vincristine and lithium carbonate as co-active ingredients of the application can obviously stimulate the generation of granulocyte colony-stimulating factor, and alleviate the neutropenia side effect caused by chemotherapy.

The application belongs to the field of medicine, and particularly relates to a medicine composition for improving the treatment effect of liver tumor and the use thereof. The medicine composition comprises chrysin and hydroxycamptothecine or vincristine, and the weight ratio of the chrysin and the hydroxycamptothecine or vincristine is 1:(1.5-5). The main components of the medicine composition, i.e. the chrysin, the hydroxycamptothecine or the vincristine, are all natural and non-toxic, can be prepared into oral preparations together with common pharmaceutically acceptable carriers, and it is proved through pharmacodynamics experiments that the two components have a synergistic effect, and can greatly improve the treatment effect of liver tumor.

This invention discloses the uses of the circular RNA circRere. Whole transcriptome sequencing was performed, and data on the circular RNA were selected. Through expression level screening, it was found that the circular RNA circRere was significantly downregulated in rats with vincristine-induced neuropathic pain. Furthermore, in vivo rat experiments demonstrated that intervention with circular RNA circRere as a supplement significantly alleviated vincristine-induced neuropathic pain. This invention provides a new drug treatment option for treating or alleviating neuropathic pain, especially neuropathic pain caused by the neurotoxic effects of vincristine, overcoming the shortcomings of traditional drug treatments or alleviators of neuropathic pain due to side effects, and providing a safer analgesic drug for clinical use.

A method for making a sulfur cathode, comprising steps oF mixing sulfur and an amount of a purine compound in a weight ratio of sulfur to purine of from less than 10:1 to greater than 2:1 to form a powder mixture; mixing the powder mixture with a solvent to form a slurry; and drying the slurry onto a current collector to form the sulfur cathode. A cathode for use in a lithium sulfur battery including sulfur; and an purine selected from the group consisting of caffeine, nicotine, morphine, codeine, quinine, atropine, ephedrine, strychnine, colchicine, theobromine, theophylline, papaverine, reserpine, coniine, harmine, ibogaine, vinblastine, vincristine, yohimbine, capsaicin, camptothecin, mitragynine, apomorphine, psilocybin, scopolamine, tetrahydrocannabinol (THC), salvinorin A, mescaline, muscarine, preferably, the purine is caffeine. Also disclosed are electrolytes and batteries.

The use of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone in the preparation of a drug for treating peripheral T-cell lymphoma (PTCL). The PTCL is preferably treatment-naïve PTCL. Other first-line and second-line drugs for treating PTCL may also be further used on the basis of the foregoing. A method for treating PTCL, the method comprising administering, to a patient, a therapeutically effective amount of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone. The combined administration of the drugs is safe and tolerable, has a small toxicity and few side effects, and can obtain a higher total objective remission rate (ORR) in treatment-naïve PTCL patients.

The present invention relates to new vincristine antibody-drug conjugates and to their use in the treatment of proliferative diseases.

The present invention relates to a simplified tetrandrine compound that specifically inhibits P-gp and reverses tumor multidrug resistance, as well as a preparation method and application. The simplified tetrandrine compound that specifically inhibits P-gp and reverses tumor multidrug resistance has the following general structure: #imgabs0# The simplified compound can efficiently reverse the multidrug resistance of various solid tumor cells such as gastric cancer, lung cancer, and esophageal cancer. The compound has low cytotoxicity and can specifically inhibit the key efflux pump protein P-gp (P-glycoprotein) that mediates tumor cell multidrug resistance. The simplified compound can be used in combination with various chemotherapy drugs such as vincristine, mitoxantrone, colchicine, and docetaxel to efficiently reverse tumor multidrug resistance both in vivo and in vitro. This type of specific P-gp inhibitor provides an alternative strategy as an anti-tumor chemotherapy sensitizer and can be used as a lead compound for the research and development of new drug-resistant tumor reversal agents.

This invention relates to the field of pharmaceutical application technology, specifically a method for preparing and applying a vincristine derivative-antibody conjugate. It involves a composition of a small molecule compound represented by general formula (I), a linker (L), and an antibody (Ab), wherein the small molecule compound is a vincristine derivative, which is conjugated to a targeting antibody via the linker to form an ADC drug with significant antitumor activity. Experiments show that this type of ADC exhibits excellent therapeutic effects in a mouse model of acute myeloid leukemia (AML), with efficacy significantly superior to first-line clinical treatment regimens (such as cytarabine combined with veneclade) and traditional vincristine monotherapy. The ADC provided by this invention has the characteristics of high targeting and low toxicity, providing a new candidate drug for the treatment of malignant tumors such as AML, and possesses significant clinical development value.